In the latest quarter, 5 analysts provided ratings for ResMed RMD, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how ...
Analysts at Catapult Wealth are positive on sleep treatment company ResMed and think it could be an ASX 200 share to buy. Catapult Wealth's analysts have been pleased with ResMed's performance in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback